Related Experiment Video

Updated: Aug 9, 2025

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

960

Current and Emerging Therapies for COVID-19 in Lung Transplantation

Daniel Z P Friedman1, Natasha N Pettit2, Erica MacKenzie3

  • 15841 South Maryland Avenue, MC 5065, Chicago, IL 60637 USA Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine.

Current Pulmonology Reports
|February 23, 2023
PubMed
Abstract

Insights

This review covers COVID-19 treatments, focusing on lung transplant recipients. Key therapies like remdesivir are essential, but others face challenges due to drug interactions and viral variants.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Transplant Surgery

Background:

  • The COVID-19 pandemic has evolved significantly over three years.
  • Numerous studies have emerged on COVID-19 epidemiology, transmission, diagnosis, and treatment.
  • Lung transplant recipients represent a vulnerable population requiring specific therapeutic considerations.

Purpose of the Study:

  • To review current COVID-19 therapeutics.
  • To emphasize the application of these treatments in lung transplant recipients.
  • To provide an updated perspective on managing COVID-19 in this specific patient group.

Main Methods:

  • Review of pertinent scientific literature on COVID-19 therapeutics.
  • Focus on studies detailing treatment efficacy and safety.
  • Emphasis on drug-drug interactions and impact of viral variants.

Main Results:

  • Remdesivir is a cornerstone therapy for mild-to-moderate COVID-19.
  • Nirmatrelvir/ritonavir, while effective for outpatients, has limited use in lung transplant recipients due to drug-drug interactions.
  • Monoclonal antibodies are valuable but increasingly impacted by emerging SARS-CoV-2 variants.

Conclusions:

  • Therapeutic strategies for COVID-19 require careful selection, especially in immunocompromised patients like lung transplant recipients.
  • Drug-drug interactions and viral evolution are critical factors influencing treatment choices.
  • Ongoing research is necessary to optimize COVID-19 management in lung transplant recipients.
Keywords:
COVID-19Lung transplantMolnupiravirMonoclonal antibodiesNirmatrelvirRemdesivir

More Related Videos

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

10.1K
Orthotopic Left Lung Transplantation in Rats08:21

Orthotopic Left Lung Transplantation in Rats

Published on: July 3, 2025

165

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
293
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
265
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
106